Offset
发表于 2025-3-28 17:30:44
http://reply.papertrans.cn/19/1877/187655/187655_41.png
Fallibility
发表于 2025-3-28 22:40:50
http://reply.papertrans.cn/19/1877/187655/187655_42.png
Keratectomy
发表于 2025-3-29 00:03:05
Remission Maintenance in Multiple Myeloma,eau”— phase of variable length, a cytokinetically quiescent state . in which myeloma cell proliferation is balanced by myeloma cell death. Complete or partial remission is not an absolute prerequisite for a plateau phase, which can be observed in patients whose best response to induction treatment i
钢笔尖
发表于 2025-3-29 03:08:21
http://reply.papertrans.cn/19/1877/187655/187655_44.png
图画文字
发表于 2025-3-29 10:31:07
Renal Diseases Associated With Multiple Myeloma and Related Plasma Cell Dyscrasias,ni syndrome (AFS) represent a group of disorders characterized by the presence of monoclonal plasma cells in bone marrow and their homogeneous immunoglobulin products—i.e., M proteins—in serum, urine, or both .. These immunoglobulin components can be nephrotoxic, as evidenced by their propensity to
scrape
发表于 2025-3-29 14:29:51
http://reply.papertrans.cn/19/1877/187655/187655_46.png
Surgeon
发表于 2025-3-29 18:30:15
New Therapeutic Approaches to Myeloma,icians have found that the most effective drugs for the treatment of myeloma belong to the following pharmacologic classes: alkylating agents (melphalan, cyclophosphamide, 1,3-bis--1-nitrosurea ), topoisomerase II inhibitors (doxorubicin and etoposide), glucocorticoids (predniso
碎片
发表于 2025-3-29 22:37:38
http://reply.papertrans.cn/19/1877/187655/187655_48.png
hallow
发表于 2025-3-30 03:57:55
978-1-61737-143-1Springer Science+Business Media New York 2004
摊位
发表于 2025-3-30 07:50:48
Biology and Management of Multiple Myeloma978-1-59259-817-5Series ISSN 2364-1134 Series E-ISSN 2364-1142